Propagation and quantification of obligate intracellular pathogens are both labor-intensive and costly undertakings. These characteristics, coupled with C. burnetii's highly infectious nature and select agent designation, complicate the most basic research endeavors. However, because highly purified and enumerated C. burnetii is essential to the proposed research, a dedicated core facility with BSL 3 containment, highly trained technical personnel, and an archival system is proposed. Thus, the purpose of the Core B is to make available to each of the 4 Montana Coxiella projects expertise in the cultivation, purification, enumeration, and archiving of phase 1 and 2 Coxiella burnetii. The core will be located at Montana State University, the location of the BSL-3 facilities, and will be directed by Allen Harmsen of Montana State University. Collaborations among projects. Core B will provide services to each of the 4 research projects of the Montana Coxiella group as well as any other RMRCE investigator needing their service. These services will include making standardized inocula of phase 1 and 2 Coxiella burnetii as well as the Crazy strain of Coxiella, as well as the services of standardized Coxiella enumeration and archival of Coxiella organisms. In addition, the two part- time technicians are trained specifically in doing lung infections in mice in the BSL-3. When not engaged in their other activities, the Core B technicians will be available to assist the 4 Montana Coxiella projects on days they sacrifice mice since these time points are labor intensive. Our BSL3 SOP requires a """"""""buddy system"""""""" and individuals are not allowed to work alone in the facility. It is much more economical to have two part time floating positions rather than for each of the individual research projects to fund full time technicians to cover these occasional, labor-intensive time points. Therefore, the core is integral and critical to the goals of each of the projects and required for consistency between projects so that results between projects can be directly compared. Core B will support the RMRCE Integrated Research Foci on Immunomodulation, Adjuvants and Vaccines (IRF 1) as well as Bacterial Therapeutics (IRF 2), and its resources will be utilized by RPs 1.1, 1.2, 1.3, and 2.4.
The RMRCE Coxiella projects are designed to collectively develop non-specific adjuvants and specific vaccines to Q fever. The Core will supply a consistent and well characterized source of C. burnetii so that results of experiments by any one of the projects can be compared to results from the other projects. Thus, the core is central to the development of immunotherapies against Q fever.
|Webb, Jessica R; Price, Erin P; Somprasong, Nawarat et al. (2018) Development and validation of a triplex quantitative real-time PCR assay to detect efflux pump-mediated antibiotic resistance in Burkholderia pseudomallei. Future Microbiol 13:1403-1418|
|York, Joanne; Nunberg, Jack H (2018) A Cell-Cell Fusion Assay to Assess Arenavirus Envelope Glycoprotein Membrane-Fusion Activity. Methods Mol Biol 1604:157-167|
|Rhodes, Katherine A; Somprasong, Nawarat; Podnecky, Nicole L et al. (2018) Molecular determinants of Burkholderia pseudomallei BpeEF-OprC efflux pump expression. Microbiology 164:1156-1167|
|Cummings, Jason E; Slayden, Richard A (2017) Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response. PLoS Negl Trop Dis 11:e0005209|
|Pettey, W B P; Carter, M E; Toth, D J A et al. (2017) Constructing Ebola transmission chains from West Africa and estimating model parameters using internet sources. Epidemiol Infect 145:1993-2002|
|Furuta, Yousuke; Komeno, Takashi; Nakamura, Takaaki (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449-463|
|Skyberg, Jerod A; Lacey, Carolyn A (2017) Hematopoietic MyD88 and IL-18 are essential for IFN-?-dependent restriction of type A Francisella tularensis infection. J Leukoc Biol 102:1441-1450|
|Plumley, Brooke A; Martin, Kevin H; Borlee, Grace I et al. (2017) Thermoregulation of Biofilm Formation in Burkholderia pseudomallei Is Disrupted by Mutation of a Putative Diguanylate Cyclase. J Bacteriol 199:|
|Randall, Linnell B; Georgi, Enrico; Genzel, Gelimer H et al. (2017) Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance. J Antimicrob Chemother 72:1258-1260|
|Podnecky, Nicole L; Rhodes, Katherine A; Mima, Takehiko et al. (2017) Mechanisms of Resistance to Folate Pathway Inhibitors in Burkholderia pseudomallei: Deviation from the Norm. MBio 8:|
Showing the most recent 10 out of 258 publications